Bajaj Healthcare zooms on entering into definitive CDMO agreement with UK/EU based customers
Bajaj Healthcare is currently trading at Rs. 365.55, up by 45.15 points or 14.09% from its previous closing of Rs. 320.40 on the BSE.
The scrip opened at Rs. 326.00 and has touched a high and low of Rs. 378.05 and Rs. 322.05 respectively. So far 132654 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 5 has touched a 52 week high of Rs. 511.00 on 16-Oct-2023 and a 52 week low of Rs. 245.05 on 31-May-2023.
Last one week high and low of the scrip stood at Rs. 378.05 and Rs. 319.95 respectively. The current market cap of the company is Rs. 986.64 crore.
The promoters holding in the company stood at 67.73%, while Institutions and Non-Institutions held 1.22% and 31.06% respectively.
Bajaj Healthcare (BHL) has entered into a definitive CDMO agreement with esteemed UK/EU based customers for the supply of 15 Active Pharmaceutical Ingredient (APIs). Under this agreement, BHL will undertake the development and supply of these molecules, which will be exclusively manufactured for its clientele. These APIs encompass a diverse range of compounds, including off-patent generics and molecules soon to be off-patent. The CDMO agreement will be executed through its in-house R&D and manufacturing capacities at Savli Vadodara, Gujarat.
Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.
